

AGENDA

7:30 AM **NETWORKING BREAKFAST**

8:00 AM **WELCOME**

Jim Palma

Chief Executive Officer, *TargetCancer Foundation*

8:30 AM **PATIENT KEYNOTE**

Leah Christoforidis

Patient Advocate

9:00 AM **SCIENTIFIC KEYNOTE**

Nonoperative Management for Mismatch Repair Deficient (MMRd) Solid Tumors

Andrea Cercek, MD

Section Head, Colorectal Cancer

Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers

Memorial Sloan Kettering Cancer Center

9:30 AM **SESSION 1: TRANSITIONING FROM DRUG-CENTRIC TO
PATIENT-CENTRIC PRECISION MEDICINE AND IMMUNOTHERAPY
TRIALS IN RARE CANCERS**

MODERATOR AND PRESENTER: Razelle Kurzrock, MD

Professor of Medicine; Associate Director, Clinical Research

Founding Director, Michels Rare Cancers Research Laboratories, *Medical College of Wisconsin*

Chief Medical Officer, *WIN Consortium for Personalized Cancer Medicine*

Young Kwang Chae, MD, MBA, MPH

Professor, Division of Hematology Oncology, Department of Medicine

Lurie Comprehensive Cancer Center of Northwestern University

Jim Palma

Chief Executive Officer, *TargetCancer Foundation*

Jens Rueter, MD

Chief Medical Officer, *The Jackson Laboratory*

Medical Director, *Maine Cancer Genomics Initiative*

10:30 AM **MORNING BREAK**

10:45 AM **EARLY CAREER INVESTIGATOR RAPID ABSTRACT PRESENTATIONS**

MODERATOR: Hetal Vig, MS, MGC, *TargetCancer Foundation*

MAPK Pathway Mutations Drive Mutant-IDH1 Inhibitor Resistance in Cholangiocarcinoma
Jinkai Wan, PhD, *Mass General Brigham Cancer Institute at MGH*

Detection and Monitoring of EWSR1 Fusions in Sarcoma Patients Using Customized Liquid Biopsies
Annie Li, MD, *Massachusetts General Hospital*

11:15 AM **SESSION 2: DRUG REPURPOSING AND RESCUE IN RARE CANCERS**

MODERATOR: A. John Iafrate, MD, PhD, *Massachusetts General Hospital*

Repurposing and Retargeting Drugs for Oncology and Rare Disease Indications: Lessons Learned
Sam Blackman, MD, PhD
Entrepreneur-in-Residence, *GV (Google Ventures)*

Expanding Tumor Agnostic Treatment Potential in HER2+ Solid Tumors
Roula Qaqish
US Medical Franchise Head, Women's Cancers, *AstraZeneca*

12:15 PM **NETWORKING LUNCH**

1:15 PM **EARLY CAREER INVESTIGATOR RAPID ABSTRACT PRESENTATIONS**

The PKA-Fusion Oncoprotein Rewires Organelle Structure and Metabolism in Fibrolamellar Carcinoma
Ilaria Gritti, PhD, *Mass General Brigham Cancer Institute at MGH*

Identifying Druggable Regulators of the Transactivation Function of the EWS-FLI1 Oncofusion in Ewing Sarcoma
Nitin Shirole, PhD, *Dana-Farber Cancer Institute*

1:45 PM **MOLECULAR TUMOR BOARD**

TCF-001 TRACK Molecular Tumor Board Case Study Presentation and Q&A
Razelle Kurzrock, MD, *Medical College of Wisconsin*, TRACK Principal Investigator
Mina Nikanjam, MD, PhD, *University of California San Diego*, TRACK Co-Principal Investigator
Vivek Subbiah, MD, *Sarah Cannon Research Institute*, TRACK Co-Principal Investigator
Bicky Thapa, MD, MS, FACP, *Dana-Farber Cancer Institute*, TRACK MTB Member

2:45 PM **AFTERNOON BREAK**

3:15 PM

AFTERNOON KEYNOTE

Why We Need Molecular Reclassification and Drug Development for Rare Cancers

Vivek Subbiah, MD

Chief, Early-Phase Drug Development, *Sarah Cannon Research Institute*

3:45 PM

PANEL DISCUSSION: THE ROLE OF JOURNALS IN ADVANCING RARE CANCER RESEARCH

MODERATOR: Vivek Subbiah, MD, *Sarah Cannon Research Institute*

Don S. Dizon, MD, FACP, FASCO

Jane F. Desforges Chair in Hematology and Oncology and Professor of Medicine, *Tufts University*

Chief, Hematology and Oncology Service Line, *Tufts Medicine*

Editor-in-Chief, *CA: A Cancer Journal for Clinicians*

Robert Kruger, PhD

Senior Executive Editor, *Cancer Discovery* and Editorial Director

American Association for Cancer Research

Ishwaria Subbiah, MD, MS, FASCO

Medical Oncology, Palliative & Integrative Oncology Physician

Associate Editor, *Journal of Clinical Oncology (JCO) Oncology Practice*

4:30 PM

CLOSING DISCUSSION: PAYING WITH OUR LIVES - ADVOCATING FOR RARE CANCER POLICY AND RESEARCH

Kristen Palma

President, *TargetCancer Foundation*

Rachel Sher, JD, MPH

Partner, *Manatt, Phelps & Phillips*

5:00 PM

COCKTAIL RECEPTION AND POSTER PRESENTATIONS

2025 MEETING CHAIR



Razelle Kurzrock, MD

Professor of Medicine, Associate Director of Clinical Research, *MCW Cancer Center and Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine*

Founding Director, *Michels Rare Cancers Research Laboratories Froedtert and Medical College of Wisconsin*

Chief Medical Officer, *WIN Consortium for Personalized Cancer Medicine*

Principal Investigator, *TCF-001 TRACK Study*

EARLY CAREER INVESTIGATOR ABSTRACTS

Jinkai Wan, Hatice Duygu Saatcioglu, Haley Ellis, Qin Xu, Hiroshi Kondo, Nabeel Bardeesy

Massachusetts General Cancer Center, Harvard Medical School

MAPK Pathway Mutations Drive Mutant-IDH1 Inhibitor Resistance in Cholangiocarcinoma

Annie Li, Prinjali Kalyan, Julia C Thierauf, Rashi Purohit, Allison C Burdi, Samantha Flynn, Bianca Gonda, Stefan T Kaluziak, Elizabeth Codd, Stacey N Dybel, Lauren L Ritterhouse, Jochen K Lennerz, Edwin Choy, Gregory M Cote, Maria J Troulis, A John Iafrate

Massachusetts General Hospital, Harvard Medical School

Detection and Monitoring of EWSR1 Fusions in Sarcoma Patients Using Customized Liquid Biopsies

Ilaria Gritti, Jinkai Wan, Joel M. Vaz, Taranjit S. Gujral, Nabeel Bardeesy

Massachusetts General Hospital, Fred Hutchinson Cancer Center

The PKA-Fusion Oncoprotein Rewires Organelle Structure and Metabolism in Fibrolamellar Carcinoma

Nitin H. Shirole and William G. Kaelin Jr.

Dana-Farber Cancer Institute

Identifying Druggable Regulators of the Transactivation Function of the EWS-FLI1 Oncofusion in Ewing Sarcoma

THANK YOU TO OUR SPONSORS

